Drug repurposing to tackle parainfluenza 3 based on multi-similarities and network proximity analysis
Given that there is currently no clinically approved drug or vaccine for parainfluenza 3 (PIV3), we applied a drug repurposing method based on disease similarity and chemical similarity to screen 2,585 clinically approved chemical drugs using PIV3 potential drugs BCX-2798 and zanamivir as our contro...
Saved in:
Published in | Frontiers in pharmacology Vol. 15 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.10.2024
|
Online Access | Get full text |
Cover
Loading…
Abstract | Given that there is currently no clinically approved drug or vaccine for parainfluenza 3 (PIV3), we applied a drug repurposing method based on disease similarity and chemical similarity to screen 2,585 clinically approved chemical drugs using PIV3 potential drugs BCX-2798 and zanamivir as our controls. Twelve candidate drugs were obtained after being screened with good disease similarity and chemical similarity ( S > 0.50, T > 0.56). When docking them with the PIV3 target protein, hemagglutinin-neuraminidase (HN), only oseltamivir was docked with a better score than BCX-2798, which indicates that oseltamivir has an inhibitory effect on PIV3. After the distance ( Z d c ) between the drug target of 14 drugs and the PIV3 disease target was measured by the network proximity method based on the PIV3 disease module, it was found that the Z d c values of amikacin, oseltamivir, ribavirin, and streptomycin were less than those of the control. Thus, oseltamivir is the best potential drug because it met all the above screening requirements. Additionally, to explore whether oseltamivir binds to HN stably, molecular dynamics simulation of the binding of oseltamivir to HN was carried out, and the results showed that the RMSD value of the complex tended to be stable within 100 ns, and the binding free energy of the complex was low (−10.60 kcal/mol). It was proved that oseltamivir screened by our drug repurposing method had the potential feasibility of treating PIV3. |
---|---|
AbstractList | Given that there is currently no clinically approved drug or vaccine for parainfluenza 3 (PIV3), we applied a drug repurposing method based on disease similarity and chemical similarity to screen 2,585 clinically approved chemical drugs using PIV3 potential drugs BCX-2798 and zanamivir as our controls. Twelve candidate drugs were obtained after being screened with good disease similarity and chemical similarity ( S > 0.50, T > 0.56). When docking them with the PIV3 target protein, hemagglutinin-neuraminidase (HN), only oseltamivir was docked with a better score than BCX-2798, which indicates that oseltamivir has an inhibitory effect on PIV3. After the distance ( Z d c ) between the drug target of 14 drugs and the PIV3 disease target was measured by the network proximity method based on the PIV3 disease module, it was found that the Z d c values of amikacin, oseltamivir, ribavirin, and streptomycin were less than those of the control. Thus, oseltamivir is the best potential drug because it met all the above screening requirements. Additionally, to explore whether oseltamivir binds to HN stably, molecular dynamics simulation of the binding of oseltamivir to HN was carried out, and the results showed that the RMSD value of the complex tended to be stable within 100 ns, and the binding free energy of the complex was low (−10.60 kcal/mol). It was proved that oseltamivir screened by our drug repurposing method had the potential feasibility of treating PIV3. |
Author | Zhong, Huayu You, Aijing Zhou, Bo Chen, Xinyue Zhang, Yonghong Jiang, Xinyi Zou, Taiyan Zhou, Chengcheng Liu, Xiaoxiao |
Author_xml | – sequence: 1 givenname: Xinyue surname: Chen fullname: Chen, Xinyue – sequence: 2 givenname: Bo surname: Zhou fullname: Zhou, Bo – sequence: 3 givenname: Xinyi surname: Jiang fullname: Jiang, Xinyi – sequence: 4 givenname: Huayu surname: Zhong fullname: Zhong, Huayu – sequence: 5 givenname: Aijing surname: You fullname: You, Aijing – sequence: 6 givenname: Taiyan surname: Zou fullname: Zou, Taiyan – sequence: 7 givenname: Chengcheng surname: Zhou fullname: Zhou, Chengcheng – sequence: 8 givenname: Xiaoxiao surname: Liu fullname: Liu, Xiaoxiao – sequence: 9 givenname: Yonghong surname: Zhang fullname: Zhang, Yonghong |
BookMark | eNpNkE1OwzAUhC1UJErpBVj5AgmxnTj2EpVfqRKb7qPn5rmYpnZkJ4JyelLogtnMaEaaxXdNZj54JOSWFbkQSt_Z_h1izgte5qzkSvPqgsyZlCLTivHZv3xFlil9FJOE1kKWc4IPcdzRiP0Y-5Cc39Eh0AG2-w5pDxGct92I_huooAYStjR4ehi7wWXJHVwH0Q0OEwXfUo_DZ4h72sfwNW3DcWqhOyaXbsilhS7h8uwLsnl63KxesvXb8-vqfp1tVV1lVT2ZMsiZsZVQpWA1slZqrIrKgJAgNbdagZGm5aCwla0SAlSpLKulMGJB-N_tNoaUItqmj-4A8diwojmhan5RNSdUzRmV-AElWWGb |
Cites_doi | 10.6026/97320630015730 10.1080/07391102.2023.2198017 10.1186/s12859-020-03643-x 10.1038/ncomms10331 10.3390/molecules21111513 10.1038/ncomms6268 10.1021/jm500759v 10.1016/j.omtn.2023.102075 10.1021/acs.jctc.1c00645 10.1038/s41421-020-0153-3 10.1016/j.compbiomed.2023.106797 10.1021/acs.est.0c03998 10.1128/JVI.01965-14 10.1080/07391102.2023.2298391 10.1186/s12920-018-0428-9 10.1055/s-0036-1584798 10.1002/rmv.2164 10.1016/j.compbiomed.2022.105468 10.1093/jac/dkq015 10.1093/cid/cix1040 10.1126/science.1257601 10.1093/bioinformatics/btm087 10.1128/AAC.49.1.398-405.2005 10.1371/journal.pcbi.1010343 10.3390/v12030342 10.1007/s40264-017-0566-6 10.1038/nbt1338 10.1016/j.jmb.2003.11.032 10.1038/nrd.2018.168 10.1002/jcc.21707 10.1099/jmm.0.068189-0 10.1016/j.compbiomed.2021.104826 10.1093/bib/bbab373 10.1080/07391102.2020.1792344 10.1016/j.antiviral.2022.105405 10.1016/j.coviro.2021.09.003 10.1073/pnas.2025581118 10.1016/j.compbiomed.2022.106377 10.1093/bib/bbab106 10.1172/JCI25669 10.1016/j.antiviral.2019.04.001 10.1038/srep24138 10.1021/ja1114198 10.1586/ers.11.32 10.2174/1574893618666230316122534 10.1021/ct2002732 10.1038/nature05114 10.1021/acsinfecdis.2c00576 10.1128/AAC.48.5.1495-1502.2004 10.1016/j.compbiomed.2020.104186 10.3390/molecules28145315 10.1007/s00894-022-05310-9 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.3389/fphar.2024.1428925 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1663-9812 |
ExternalDocumentID | 10_3389_fphar_2024_1428925 |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW KQ8 M~E O5R O5S OK1 P2P PGMZT RNS RPM |
ID | FETCH-LOGICAL-c875-57c878be21bf5384317e1d69e505ba36a692f98ab6bd2a8ed6d833a848f1763b3 |
ISSN | 1663-9812 |
IngestDate | Wed Oct 02 14:35:49 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c875-57c878be21bf5384317e1d69e505ba36a692f98ab6bd2a8ed6d833a848f1763b3 |
OpenAccessLink | https://doi.org/10.3389/fphar.2024.1428925 |
ParticipantIDs | crossref_primary_10_3389_fphar_2024_1428925 |
PublicationCentury | 2000 |
PublicationDate | 2024-10-1 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-1 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Frontiers in pharmacology |
PublicationYear | 2024 |
References | Xi (B49) 2023; 34 Davies (B13) 2010; 65 Nayar (B31) 2011; 7 Tao (B42) 2022; 18 Laborda (B23) 2016; 21 Schmidt (B38) 2011; 5 Sinclair (B39) 2017; 40 Guney (B18) 2016; 7 Moscona (B30) 2005; 115 Wang (B46) 2022; 23 Koulgi (B21) 2021; 39 Valdés-Tresanco (B44) 2021; 17 Kumar (B22) 2021; 130 Bhasin (B7) 2022; 28 Parihar (B33) 2022; 145 Tang (B41) 2023; 18 Branche (B8) 2016; 37 Rota (B36) 2023; 9 Lawrence (B24) 2004; 335 Mizuta (B28) 2014; 63 Dai (B11) 2020; 54 Pushpakom (B34) 2019; 18 Aggarwal (B1) 2020; 12 Morselli Gysi (B29) 2021; 118 Chibanga (B9) 2019; 167 Contreras (B10) 2021; 51 Yildirim (B51) 2007; 25 El-Deeb (B15) 2014; 57 Li (B25) 2018; 11 Sonkar (B40) 2021; 137 Durai (B14) 2020; 21 Alymova (B3) 2004; 48 Awan (B4) 2024 Gu (B16) 2011; 133 B12 Russell (B37) 2006; 443 Zhou (B53) 2020; 6 Guillon (B17) 2014; 5 Yin (B52) 2023; 28 Malosh (B26) 2018; 66 Yap (B50) 2011; 32 Wang (B47) 2007; 23 Bailly (B5) 2016; 6 Alymova (B2) 2005; 49 Van Den Bergh (B45) 2022; 207 Menche (B27) 2015; 347 Rafeek (B35) 2021; 31 Indumathi (B19) 2019; 15 Tayubi (B43) 2023; 152 Palmer (B32) 2014; 88 Khan (B20) 2023; 158 Bashir (B6) 2023; 42 Wang (B48) 2021; 22 |
References_xml | – volume: 15 start-page: 730 year: 2019 ident: B19 article-title: Molecular docking analysis of zanamavir with haem agglutinin neuraminidase of human para influenza virus type 3 publication-title: Bioinformation doi: 10.6026/97320630015730 contributor: fullname: Indumathi – volume: 42 start-page: 1099 year: 2023 ident: B6 article-title: Integrated virtual screening and molecular dynamics simulation approaches revealed potential natural inhibitors for DNMT1 as therapeutic solution for triple negative breast cancer publication-title: J. Biomol. Struct. Dyn. doi: 10.1080/07391102.2023.2198017 contributor: fullname: Bashir – volume: 21 start-page: 309 year: 2020 ident: B14 article-title: Evolutionary chemical binding similarity approach integrated with 3D-QSAR method for effective virtual screening publication-title: BMC Bioinforma. doi: 10.1186/s12859-020-03643-x contributor: fullname: Durai – volume: 7 start-page: 10331 year: 2016 ident: B18 article-title: Network-based in silico drug efficacy screening publication-title: Nat. Commun. doi: 10.1038/ncomms10331 contributor: fullname: Guney – volume: 21 start-page: 1513 year: 2016 ident: B23 article-title: Influenza neuraminidase inhibitors: synthetic approaches, derivatives and biological activity publication-title: Molecules doi: 10.3390/molecules21111513 contributor: fullname: Laborda – volume: 5 start-page: 5268 year: 2014 ident: B17 article-title: Structure-guided discovery of potent and dual-acting human parainfluenza virus haemagglutinin-neuraminidase inhibitors publication-title: Nat. Commun. doi: 10.1038/ncomms6268 contributor: fullname: Guillon – volume: 57 start-page: 7613 year: 2014 ident: B15 article-title: Exploring human parainfluenza virus type-1 hemagglutinin-neuraminidase as a target for inhibitor discovery publication-title: J. Med. Chem. doi: 10.1021/jm500759v contributor: fullname: El-Deeb – volume: 34 start-page: 102075 year: 2023 ident: B49 article-title: Unveiling the mechanisms of nephrotoxicity caused by nephrotoxic compounds using toxicological network analysis publication-title: Mol. Ther. Nucleic Acids doi: 10.1016/j.omtn.2023.102075 contributor: fullname: Xi – volume: 17 start-page: 6281 year: 2021 ident: B44 article-title: gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS publication-title: J. Chem. Theory Comput. doi: 10.1021/acs.jctc.1c00645 contributor: fullname: Valdés-Tresanco – volume: 6 start-page: 14 year: 2020 ident: B53 article-title: Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 publication-title: Cell Discov. doi: 10.1038/s41421-020-0153-3 contributor: fullname: Zhou – volume: 158 start-page: 106797 year: 2023 ident: B20 article-title: Structure-based design of promising natural products to inhibit thymidylate kinase from Monkeypox virus and validation using free energy calculations publication-title: Comput. Biol. Med. doi: 10.1016/j.compbiomed.2023.106797 contributor: fullname: Khan – volume: 54 start-page: 15235 year: 2020 ident: B11 article-title: Probing the mechanism of hepatotoxicity of hexabromocyclododecanes through toxicological network analysis publication-title: Environ. Sci. Technol. doi: 10.1021/acs.est.0c03998 contributor: fullname: Dai – volume: 88 start-page: 13495 year: 2014 ident: B32 article-title: Circulating clinical strains of human parainfluenza virus reveal viral entry requirements for in vivo infection publication-title: J. Virol. doi: 10.1128/JVI.01965-14 contributor: fullname: Palmer – start-page: 1 year: 2024 ident: B4 article-title: In silico exploration of the potential inhibitory activities of in-house and ZINC database lead compounds against alpha-glucosidase using structure-based virtual screening and molecular dynamics simulation approach publication-title: J. Biomol. Struct. Dyn. doi: 10.1080/07391102.2023.2298391 contributor: fullname: Awan – volume: 11 start-page: 112 year: 2018 ident: B25 article-title: Novel disease syndromes unveiled by integrative multiscale network analysis of diseases sharing molecular effectors and comorbidities publication-title: BMC Med. Genomics doi: 10.1186/s12920-018-0428-9 contributor: fullname: Li – volume: 37 start-page: 538 year: 2016 ident: B8 article-title: Parainfluenza virus infection publication-title: Semin. Respir. Crit. Care Med. doi: 10.1055/s-0036-1584798 contributor: fullname: Branche – volume: 31 start-page: e2164 year: 2021 ident: B35 article-title: A review on disease burden and epidemiology of childhood parainfluenza virus infections in Asian countries publication-title: Rev. Med. Virol. doi: 10.1002/rmv.2164 contributor: fullname: Rafeek – volume: 145 start-page: 105468 year: 2022 ident: B33 article-title: Phytochemicals-based targeting RdRp and main protease of SARS-CoV-2 using docking and steered molecular dynamic simulation: a promising therapeutic approach for Tackling COVID-19 publication-title: Comput. Biol. Med. doi: 10.1016/j.compbiomed.2022.105468 contributor: fullname: Parihar – volume: 65 start-page: ii5 year: 2010 ident: B13 article-title: Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkq015 contributor: fullname: Davies – volume: 66 start-page: 1492 year: 2018 ident: B26 article-title: Efficacy and safety of oseltamivir in children: systematic review and individual patient data meta-analysis of randomized controlled trials publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cix1040 contributor: fullname: Malosh – volume: 347 start-page: 1257601 year: 2015 ident: B27 article-title: Disease networks. Uncovering disease-disease relationships through the incomplete interactome publication-title: Science doi: 10.1126/science.1257601 contributor: fullname: Menche – volume: 23 start-page: 1274 year: 2007 ident: B47 article-title: A new method to measure the semantic similarity of GO terms publication-title: Bioinformatics doi: 10.1093/bioinformatics/btm087 contributor: fullname: Wang – volume: 49 start-page: 398 year: 2005 ident: B2 article-title: The novel parainfluenza virus hemagglutinin-neuraminidase inhibitor BCX 2798 prevents lethal synergism between a paramyxovirus and Streptococcus pneumoniae publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.49.1.398-405.2005 contributor: fullname: Alymova – volume: 18 start-page: e1010343 year: 2022 ident: B42 article-title: Binding mechanism of oseltamivir and influenza neuraminidase suggests perspectives for the design of new anti-influenza drugs publication-title: PLoS Comput. Biol. doi: 10.1371/journal.pcbi.1010343 contributor: fullname: Tao – volume: 12 start-page: 342 year: 2020 ident: B1 article-title: Structural insight into paramyxovirus and Pneumovirus entry inhibition publication-title: Viruses doi: 10.3390/v12030342 contributor: fullname: Aggarwal – volume: 40 start-page: 1205 year: 2017 ident: B39 article-title: The ribavirin pregnancy registry: an interim analysis of potential teratogenicity at the mid-point of enrollment publication-title: Drug Saf. doi: 10.1007/s40264-017-0566-6 contributor: fullname: Sinclair – volume: 25 start-page: 1119 year: 2007 ident: B51 article-title: Drug-target network publication-title: Nat. Biotechnol. doi: 10.1038/nbt1338 contributor: fullname: Yildirim – volume: 335 start-page: 1343 year: 2004 ident: B24 article-title: Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III publication-title: J. Mol. Biol. doi: 10.1016/j.jmb.2003.11.032 contributor: fullname: Lawrence – volume: 18 start-page: 41 year: 2019 ident: B34 article-title: Drug repurposing: progress, challenges and recommendations publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2018.168 contributor: fullname: Pushpakom – volume: 32 start-page: 1466 year: 2011 ident: B50 article-title: PaDEL-descriptor: an open source software to calculate molecular descriptors and fingerprints publication-title: J. Comput. Chem. doi: 10.1002/jcc.21707 contributor: fullname: Yap – volume: 63 start-page: 570 year: 2014 ident: B28 article-title: Molecular evolution of the haemagglutinin-neuraminidase gene in human parainfluenza virus type 3 isolates from children with acute respiratory illness in Yamagata prefecture, Japan publication-title: J. Med. Microbiol. doi: 10.1099/jmm.0.068189-0 contributor: fullname: Mizuta – volume: 137 start-page: 104826 year: 2021 ident: B40 article-title: Repurposing of gastric cancer drugs against COVID-19 publication-title: Comput. Biol. Med. doi: 10.1016/j.compbiomed.2021.104826 contributor: fullname: Sonkar – volume: 23 start-page: bbab373 year: 2022 ident: B46 article-title: Identification of potential therapeutic targets and mechanisms of COVID-19 through network analysis and screening of chemicals and herbal ingredients publication-title: Brief. Bioinform doi: 10.1093/bib/bbab373 contributor: fullname: Wang – volume: 39 start-page: 5735 year: 2021 ident: B21 article-title: Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CLpro) publication-title: J. Biomol. Struct. Dyn. doi: 10.1080/07391102.2020.1792344 contributor: fullname: Koulgi – volume: 207 start-page: 105405 year: 2022 ident: B45 article-title: Antiviral strategies against human metapneumovirus: targeting the fusion protein publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2022.105405 contributor: fullname: Van Den Bergh – volume: 51 start-page: 34 year: 2021 ident: B10 article-title: Antivirals targeting paramyxovirus membrane fusion publication-title: Curr. Opin. Virol. doi: 10.1016/j.coviro.2021.09.003 contributor: fullname: Contreras – volume: 118 start-page: e2025581118 year: 2021 ident: B29 article-title: Network medicine framework for identifying drug-repurposing opportunities for COVID-19 publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.2025581118 contributor: fullname: Morselli Gysi – volume: 152 start-page: 106377 year: 2023 ident: B43 article-title: Identification of potential inhibitor targeting KRAS mutation in Papillary Thyroid Carcinoma through molecular docking and dynamic simulation analysis publication-title: Comput. Biol. Med. doi: 10.1016/j.compbiomed.2022.106377 contributor: fullname: Tayubi – volume: 22 start-page: bbab106 year: 2021 ident: B48 article-title: Network-based modeling of herb combinations in traditional Chinese medicine publication-title: Brief. Bioinform doi: 10.1093/bib/bbab106 contributor: fullname: Wang – volume: 115 start-page: 1688 year: 2005 ident: B30 article-title: Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease publication-title: J. Clin. Invest. doi: 10.1172/JCI25669 contributor: fullname: Moscona – volume: 167 start-page: 89 year: 2019 ident: B9 article-title: New antiviral approaches for human parainfluenza: inhibiting the haemagglutinin-neuraminidase publication-title: Antivir. Res. doi: 10.1016/j.antiviral.2019.04.001 contributor: fullname: Chibanga – volume: 6 start-page: 24138 year: 2016 ident: B5 article-title: A dual drug regimen synergistically blocks human parainfluenza virus infection publication-title: Sci. Rep. doi: 10.1038/srep24138 contributor: fullname: Bailly – volume: 133 start-page: 10817 year: 2011 ident: B16 article-title: Free energy calculations on the two drug binding sites in the M2 proton channel publication-title: J. Am. Chem. Soc. doi: 10.1021/ja1114198 contributor: fullname: Gu – volume: 5 start-page: 515 year: 2011 ident: B38 article-title: Progress in the development of human parainfluenza virus vaccines publication-title: Expert Rev. Respir. Med. doi: 10.1586/ers.11.32 contributor: fullname: Schmidt – volume: 18 start-page: 484 year: 2023 ident: B41 article-title: Exploring the hepatotoxicity of drugs through machine learning andNetwork toxicological methods publication-title: CBIO doi: 10.2174/1574893618666230316122534 contributor: fullname: Tang – ident: B12 article-title: Darden, T., York, D., and Pedersen, L. (1993). Particle mesh Ewald: an N log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089–10092. 10.1063/1.464397.[CrossRef Exact] [CS: 100]Refstyled – volume: 7 start-page: 3354 year: 2011 ident: B31 article-title: Comparison of tetrahedral order, liquid state anomalies, and hydration behavior of mTIP3P and TIP4P water models publication-title: J. Chem. Theory Comput. doi: 10.1021/ct2002732 contributor: fullname: Nayar – volume: 443 start-page: 45 year: 2006 ident: B37 article-title: The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design publication-title: Nature doi: 10.1038/nature05114 contributor: fullname: Russell – volume: 9 start-page: 617 year: 2023 ident: B36 article-title: Design, synthesis, and antiviral evaluation of sialic acid derivatives as inhibitors of newcastle disease virus hemagglutinin-neuraminidase: a translational study on human parainfluenza viruses publication-title: ACS Infect. Dis. doi: 10.1021/acsinfecdis.2c00576 contributor: fullname: Rota – volume: 48 start-page: 1495 year: 2004 ident: B3 article-title: Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.48.5.1495-1502.2004 contributor: fullname: Alymova – volume: 130 start-page: 104186 year: 2021 ident: B22 article-title: A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment publication-title: Comput. Biol. Med. doi: 10.1016/j.compbiomed.2020.104186 contributor: fullname: Kumar – volume: 28 start-page: 5315 year: 2023 ident: B52 article-title: LSD1-Based reversible inhibitors virtual screening and binding mechanism computational study publication-title: Molecules doi: 10.3390/molecules28145315 contributor: fullname: Yin – volume: 28 start-page: 319 year: 2022 ident: B7 article-title: Epicatechin analogues may hinder human parainfluenza virus infection by inhibition of hemagglutinin neuraminidase protein and prevention of cellular entry publication-title: J. Mol. Model doi: 10.1007/s00894-022-05310-9 contributor: fullname: Bhasin |
SSID | ssj0000399364 |
Score | 2.3988838 |
Snippet | Given that there is currently no clinically approved drug or vaccine for parainfluenza 3 (PIV3), we applied a drug repurposing method based on disease... |
SourceID | crossref |
SourceType | Aggregation Database |
Title | Drug repurposing to tackle parainfluenza 3 based on multi-similarities and network proximity analysis |
Volume | 15 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEF60XryIT3wzB_FSU5tnk6NUpQiKhwrFS9hNNpqDibQN2P56Z3bTNGoF6yUJyzIkmW93ZnZnvmXszCdKkoBODWib3HBigWNORr4hTOG7iROgUaFA8f7B6z05dwN3MF_KVtUlY9GKpgvrSv6jVWxDvVKV7BKarYRiAz6jfvGKGsbrn3R8PSxeaNUff1auYn5yJDlt1jaJ0jvVB5BMedNukrWKaWdAZRAao_QtxZhW0amq_YNMp4NTvtYH1TwRLZOmK6m7r7dEd0CHZ6vk8znrdbUu3y2LPQZpNikqzDy_5oUCUl4l7KTlOjV1TGv9dGuv4JOiviBhOVVq22wORSfGCPwyO1ouaJtNvO6iORxjZqJATegjWiS_RaRwgS6P_kqY_c2QVemFGNiQlFDJCElGWMpYZWtWJ3A7tdhbmWxy0xTVWPWiusCKxFz-fJWaE1PzRvqbbKMMI-BKY2KLrchsm50_ao1MLqA_L6sbXcA5PNZ0tcMkAQdqwIFxDho48AU4YIMCDuQZ_AQOIHCgBA5UwIEZcHZZ__am3-0Z5XkbRoRRq-F28OYLaZkiQTNInqU0Yy-Q6CQLbnvcC6wk8LnwRGxxX8Ze7Ns2x9GemGilhL3HGlmeyX0GccLRz4541DZpvDs84h2Lc8tzuYjQhz1gzdn_C981q0r4u9IOl-p9xNbnqDxmjfGwkCfoOI7FqVL6J6NZcZE |
link.rule.ids | 315,786,790,870,27957,27958 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Drug+repurposing+to+tackle+parainfluenza+3+based+on+multi-similarities+and+network+proximity+analysis&rft.jtitle=Frontiers+in+pharmacology&rft.au=Chen%2C+Xinyue&rft.au=Zhou%2C+Bo&rft.au=Jiang%2C+Xinyi&rft.au=Zhong%2C+Huayu&rft.date=2024-10-01&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=15&rft_id=info:doi/10.3389%2Ffphar.2024.1428925&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fphar_2024_1428925 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |